BidaskClub upgraded shares of Blueprint Medicines (NASDAQ:BPMC) from a hold rating to a buy rating in a research note issued to investors on Friday morning.
Several other brokerages have also recently commented on BPMC. ValuEngine cut Blueprint Medicines from a hold rating to a sell rating in a report on Friday, December 1st. Raymond James Financial set a $82.00 target price on Blueprint Medicines and gave the stock a buy rating in a report on Sunday, December 10th. Wedbush restated an outperform rating and set a $82.00 target price (up previously from $70.00) on shares of Blueprint Medicines in a report on Monday, November 6th. Zacks Investment Research cut Blueprint Medicines from a buy rating to a hold rating in a report on Thursday, January 11th. Finally, Goldman Sachs Group increased their target price on Blueprint Medicines from $82.00 to $99.00 and gave the stock a buy rating in a report on Monday, December 11th. Two investment analysts have rated the stock with a sell rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $84.20.
Shares of Blueprint Medicines (BPMC) opened at $88.02 on Friday. The company has a current ratio of 15.98, a quick ratio of 15.98 and a debt-to-equity ratio of 0.02. Blueprint Medicines has a 1-year low of $32.43 and a 1-year high of $92.50.
In related news, Director Daniel Lynch sold 12,500 shares of the firm’s stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $80.42, for a total value of $1,005,250.00. Following the transaction, the director now owns 174,342 shares in the company, valued at $14,020,583.64. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Kate Haviland sold 6,775 shares of the firm’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $74.93, for a total value of $507,650.75. Following the completion of the transaction, the insider now owns 12,649 shares in the company, valued at approximately $947,789.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,775 shares of company stock worth $2,822,601. 3.40% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its stake in Blueprint Medicines by 31.5% in the second quarter. Wells Fargo & Company MN now owns 28,827 shares of the biotechnology company’s stock valued at $1,462,000 after buying an additional 6,899 shares during the period. UBS Asset Management Americas Inc. lifted its stake in Blueprint Medicines by 160.2% in the second quarter. UBS Asset Management Americas Inc. now owns 13,051 shares of the biotechnology company’s stock valued at $661,000 after buying an additional 8,036 shares during the period. Vanguard Group Inc. lifted its stake in Blueprint Medicines by 16.0% in the second quarter. Vanguard Group Inc. now owns 1,415,963 shares of the biotechnology company’s stock valued at $71,746,000 after buying an additional 195,517 shares during the period. California Public Employees Retirement System acquired a new position in Blueprint Medicines in the second quarter valued at about $314,000. Finally, Parametric Portfolio Associates LLC lifted its stake in Blueprint Medicines by 36.8% in the second quarter. Parametric Portfolio Associates LLC now owns 12,838 shares of the biotechnology company’s stock valued at $651,000 after buying an additional 3,454 shares during the period. Institutional investors and hedge funds own 89.28% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was published by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/3222925/blueprint-medicines-bpmc-raised-to-buy-at-bidaskclub.html.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease.
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.